NewGenIvf Group Limited Announces Closing of $2.5 Million Underwritten Offering
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
NewGenIvf Group (NIVF) closed a firm-commitment underwritten offering that raised approximately $2.5 million in gross proceeds before underwriting fees and other offering expenses.
At closing, the offering comprised 9,501,148 Class A ordinary shares at $0.035 each and pre-funded warrants at $0.03499 each to buy up to 61,927,422 shares. NewGenIvf plans to use approximately $625,000 of gross proceeds to repurchase $584,112 in Exchange Note principal. The company expects to use net proceeds and existing cash for Nodexus cytometry technology and assisted reproductive services expansion and commercialization, further prediction-market and digital-asset/AI investments, UAE real estate interests and general corporate purposes.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointClosed underwritten offering raised approximately $2.5 million in gross proceeds 45× market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.Nodexus cytometry technology and assisted reproductive services are slated for commercialization and expansion using net proceeds and existing cash
- Minor point. Forward-looking: it has not happened yet and may not happen.Planned Exchange Note repurchase allocates approximately $625,000 of gross proceeds to repurchase $584,112 in principal
- Minor point. Forward-looking: it has not happened yet and may not happen.Further prediction-market and digital-asset/AI investments are among the company's planned uses of net proceeds and existing cash
Negative
- Major pointShare dilution from 9,501,148 Class A ordinary shares at $0.035 each, with potential further dilution from $0.03499 pre-funded warrants covering up to 61,927,422 shares
- Minor pointUnderwriting fees and other offering expenses are payable by NewGenIvf and reduce gross proceeds
News Explained
Management retains broad discretion over how the net proceeds are applied among the listed uses.
At the completed offering, NewGenIvf sold pre-funded warrants for up to 61,927,422 shares, immediately exercisable at
Key Figures
- Gross proceeds
- approximately $2.5 million
- Underwritten offering; before fees and expenses
- Class A Ordinary Shares sold
- 9,501,148 shares
- Offering at closing
- Pre-funded warrants
- up to 61,927,422 shares
- Shares purchasable under warrants at closing
- Share offering price
- $0.035 per share
- Class A Ordinary Shares
- Warrant offering price
- $0.03499 per warrant
- Pre-funded warrants
- Warrant exercise price
- $0.00001 per warrant
- Pre-funded warrants
- Gross proceeds allocated to note repurchase
- approximately $625,000
- Exchange Note repurchase
- Exchange Note principal repurchased
- $584,112
- Exchange Note repurchase
Key Terms
firm commitment financial
pre-funded warrants financial
shelf registration statement regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
BANGKOK, Nov. 20, 2026 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF) (the “Company”), a technology-driven, diversified growth company, today announced the closing of its previously announced firm commitment underwritten offering with gross proceeds to the Company of approximately
The offering consisted of 71,428,570 Class A Ordinary Shares (or pre-funded warrants to purchase Class A Ordinary Shares in lieu thereof (the “Pre-Funded Warrants”)). At closing, the offering comprised 9,501,148 Class A Ordinary Shares and Pre-Funded Warrants to purchase up to 61,927,422 Class A Ordinary Shares. The offering price per Class A Ordinary Share was
Aggregate gross proceeds to the Company were approximately
Aegis Capital Corp. acted as the sole book-running manager for the offering. Han Kun Law Offices LLP acted as U.S. counsel to the Company. Kaufman & Canoles, P.C. acted as U.S. counsel to Aegis Capital Corp.
The offering was made pursuant to an effective shelf registration statement on Form F-3 (No. 333-299649) previously filed with the U.S. Securities and Exchange Commission (SEC) and declared effective by the SEC on November 12, 2026. A final prospectus supplement and accompanying prospectus describing the terms of the offering have been filed with the SEC and are available on the SEC’s website located at www.sec.gov. Electronic copies of the final prospectus supplement and the accompanying prospectus may be obtained by contacting Aegis Capital Corp., Attention: Syndicate Department, 1345 Avenue of the Americas, 27th floor, New York, NY 10105, by email at syndicate@aegiscap.com, or by telephone at +1 (212) 813-1010.
Interested parties should read in their entirety the prospectus supplement and the accompanying prospectus and the other documents that the Company has filed with the SEC that are incorporated by reference in such prospectus supplement and the accompanying prospectus, which provide more information about the Company and the offering.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About NewGenIvf Group Limited
NewGenIvf Group Limited is a technology-forward, diversified growth company pursuing opportunities across real estate development, digital asset innovation, and reproductive health solutions. The Company operates through NewGenProperty, focused on real estate development projects in Ras Al Khaimah, United Arab Emirates; NewGenDigital, focused on digital asset and decentralized-finance solutions; and NewGenSup, focused on health and longevity products and solutions. The Company’s legacy business includes IVF and assisted reproductive treatment services across Asia. To learn more, visit www.nivf.global. Information contained on, or accessible through, the Company’s website is not incorporated by reference into this press release.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, including without limitation statements regarding the anticipated use of proceeds from the offering, the Company’s product development and business prospects, and can be identified by the use of words such as “may,” “will,” “expect,” “project,” “estimate,” “anticipate,” “plan,” “believe,” “potential,” “should,” “continue” or the negative versions of those words or other comparable words. Forward-looking statements are not guarantees of future actions or performance. These forward-looking statements are based on information currently available to the Company and its current plans or expectations and are subject to a number of risks and uncertainties that could significantly affect current plans. Should one or more of these risks or uncertainties materialize, or the underlying assumptions prove incorrect, actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, performance, or achievements. For a discussion of the risks and uncertainties that could cause actual results to differ materially, see the section entitled “Risk Factors” in the Company’s Annual Report on Form 20-F for the year ended December 31, 2025 and in the final prospectus supplement relating to the offering. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Investor Contact:
ICR, LLC
Robin Yang
Phone: +1 (212) 537-4406
Email: Newgenivf.IR@icrinc.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.